Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-11-21
1996-03-05
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514922, A61K 3700
Patent
active
054968046
ABSTRACT:
A method of treating a host using taxol comprising administering granulocyte colony-stimulating factor to the host being treated with taxol. The present inventive method allows for increased levels of taxol to be administered to the host in the treatment of various conditions, particularly with respect to ovarian tumors.
REFERENCES:
patent: 4942184 (1990-07-01), Haugwitz et al.
patent: 4958009 (1990-09-01), Bjorn et al.
patent: 4961926 (1990-10-01), Garbrilore
patent: 5104651 (1992-04-01), Boone et al.
patent: 5157049 (1992-10-01), Haugwitz et al.
Antman, "G-CSF and GM-CSF in Clinical Trials," Yale J. Biol. Med., 63, 387-410 (1990).
Bronchud et al., "Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer," Br. J. Cancer, 56, 809-813 (1987).
Brown et al., "A Phase I Trial of Taxol Given by a 6-Hour Intravenous Infusion," J. Clin. Oncol., 9, 1261-1267 (1991).
Budman et al., "Initial Findings of CALGB 8541: A Dose and Dose Intensity Trail of Cyclophosphamide (C), Doxorubicin (A), and 5-Fluorouracil (F) as Adjuvant Treatment of Dtage II, Node +, Female Breast Cancer," Proc. Am. Soc. Clin. Oncol., 11, Abst. #29, 51 (1992).
Buller et al., "CA 125 regression: A model for epithelial ovarian cancer response," Am. J. Obstet. Gynecol., 165, 360-367 (1991).
Chabner, "Taxol," Principles & Practice on Oncology Updates, 5, 1-19 (1991).
Chang et al., "Phase II Study of Taxol in Patients with Stage IV Non-Small Cell Lung Cancer; The Eastern Cooperative Oncology Group Results," Proc. Am. Soc. Clin. Oncol., 11, Abst. #981, 293 (1992).
Crawford et al., "Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer," New Engl. J. Med., 325, 164-170 (1991).
DeVita et al., "The Chemotherapy of Lymphomas: Looking Back, Moving Forward," Cancer Res., 47, 5810-5824 (1987).
DeVita, "The influence of information on drug resistance on protocol design," Annals of Oncology 2, 93-106 (1991).
DeVita et al., "Treatment of Hodgkin's Disease," J. Natl. Cancer Inst. Monographs No. 10 (1990).
Donehower et al., "Phase I Trail of Taxol in Patients with Advanced Cancer," Cancer Treat. Rep. 71, 1171-1177 (1987).
Einzig et al., "Phase II study of taxol in patients with advanced ovarian cancer," Proc. Am. Assoc. Cancer Res., 31, Abst. #1114, 187 (1990).
Einzig et al., "Taxol: A new agent active in melanoma and ovarian cancer," Cancer Treat. Res., 58, 89-100 (1991).
Einzig et al., "A Phase II Study of Taxol in Patients with Malignant Melanoma," Invest. New Drugs, 9, 59-64 (1991).
Einzig et al., "Phase II Trail of Taxol in Patients with Metastatic Renal Cell Carcinoma," Cancer Invest. 9, 133-136 (1991).
Forastiere et al., "Phase I Trail of Taxol and Cisplatin+G-CSF in Solid Tumors," Proc. Am. Soc. Cancer Oncol., 11, Abst. #289, 117 (1992).
Frost & Sullivan Reports, "Colony-stimulating Factors (CSF)," in: The U.S. Market for Cancer Therapy Products, vol. I, 142-149, (Frost & Sullivan, Inc., New York, 1991).
Gabrilove et al., "Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium," New Engl. J. Med., 318, 1414-1422 (1988).
Holmes et al., "Phase II Trail of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer," J. Natl. Cancer Inst., 83, 1797-1805 (1991).
Holmes et al., "Phase II Study of Taxol and Doxorubicin with G-CSF in Patients Without Prior Chemotherapy for Metastatic Breast Cancer," Proc. Am. Soc. Clin. Oncol., 11, Abst. #66, 60 (1991).
Hrynuik et al., "Analysis of Dose Intensity for Adjuvant Chemotherapy Trials in Stage II Breast Cancer," J. Clin. Oncol. 4, 1162-1170 (1986).
Kris et al., "Phase I Trial of Taxol Given as a 3-Hour Infusion Every 21 Days," Cancer Treat. Rep. 70, 605-607 (1987).
Kumar, "Taxol induced Polymerization of Purified Tubulin," J. Biol. Chem., 256, 10435-10441 (1981).
Legha et al., "A Phase II Trial of Taxol in Metastatic Melanoma," Cancer, 65, 2478-2481 (1990).
Levin et al., "The Application of Dose Intensity to Problems in Chemotherapy of Ovarian and Endometrial Cancer," Semin. Oncol., 14 (suppl. 4), 12-19 (1987).
Levin et al., "Dose Intensity Analysis of Chemotherapy Regimens in Ovarian Carcinoma," J. Clin. Oncol. 5, 756-767 (1989).
Lipton et al., "Taxol produces a predominantly sensory neuropathy," Neurology 39, 368-373 (1989).
Lund et al., "Comparison of the Predictive Power of Different Prognostic Indices for Overall Survival in Patients with Advanced Ovarian Carcinoma," Cancer Res., 50, 4626-4629 (1990).
Malkasian et al., "Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary," An. J. Obstet. Gynecol., 149, 274-284 (1984).
Markman et al., "Responses to Second-Line Cisplatin-Based Intraperitoneal Therapy in Ovarian Cancer: Influence of a Prior Response to Intravenous Cisplatin," J. Clin. Oncol., 9, 1801-1805 (1991).
Mayer et al., "Comparative Evaluation of Intensitve Post-Remission Therapy with Different Dose Schedules of Ara-C in Adults with Acute Myeloid Leukemia (AML): Initial Results of a CALGB Phase III Study," Proc. Am. Soc. Clin. Oncol. 11, Abst. #853, 261 (1992).
McGuire et al., "Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms," Ann. Intern. Med. 111, 273-279 (1989).
Omura et al., "Long-Term Follow-Up and Prognostic Factor Analysis in Advanced Ovarian Carcinoma: The Gynecologic Oncology Group Experience," J. Clin. Oncol., 9, 1138-1150 (1991).
Ozols et al., "Summary of Symposium: Biology and Therapy of Ovarian Cancer," Semin. Oncol., 18, 297-306 (1991).
Reed et al., "Suramin in Advanced Platinum-resistant Ovarian Cancer," Eur. J. Cancer, 28A, 864-866 (1992).
Reed et al., "5-Fluorouracil and Leucovorin in Platinum-Refractory Advanced Stage Ovarian Carcinoma," Gynecol. Oncol., 46, 326-329.
Roesler et al., "In vitro functions of neutrophils induced by treatment with rhG-CSF in severe congenital neutropenia," Eur. J. Haematol., 46, 112-118 (1991).
Rothenberg et al., "Changing concepts in the management of epithelial ovarian and cervical cancers," Med. J. of Australia, 148, 354-363 (1988).
Rowinsky et al., "Phase I and Phamacodynamic Study of Taxol in Refractory Acute Leukemias," Cancer Res., 49, 4640-4647 (1989).
Rowinsky et al., "Taxol: A Novel Investigational Antimicrotubule Agent," J. Natl. Cancer Inst., 82, 1247-1259 (1990).
Rowinsky et al., "Cardiac Disturbances During the Administration of Taxol," J. Clin. Oncol., 9, 1704-1712 (1991).
Sarosy et al., "Taxol Dose Intensification in Patients with Recurrent Ovarian Cancer," Proc. Am. Soc. Clin. Oncol., 11, Abst. #716, 226 (1992).
Scarffe et al., "Clinical studies of granulocyte colony stimulating factor," Cancer Surveys, 9, 115-130 (1990).
Schiff et al., "Promotion of microtubule assembly in vitro by taxol," Nature, 277, 655-667 (1979).
Souza et al., "Recombinant Human Granuloctye Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid Cells," Science, 232, 61-65 (1986).
Thigpen et al., "Phase II trial of taxol as second-line therapy for ovarian carcinoma," Proc. Am. Soc. Clin. Onc., 9, Abst. #604, 156 (1990).
Weiss et al., "Hypersensitivity Reactions From Taxol," J. Clin. Oncol., 8, 1263-1268 (1990).
Welte et al., "Purification and biological characterization of human pluripotent hematopoietic colony stimulating factor," Proc. Natl. Acad. Sci., 82, 1526-1530 (1985).
Wiernik et al., "Phase I Trial of Taxol Given as a 24-Hour Infusion Every 21 Days: Responses Observed in Metastatic Melanoma," J. Clin. Oncol., 5, 1232-1239 (1987).
Wiernik et al., "Phase I Clinical and Pharmacokinetic Study of Taxol," Cancer Res. 47, 2486-2493 (1987).
Yoshida et al., "Effect of Granulocyte Colony-Stimulating Factor on Neutropenia Due to Chemotherapy for Non-Hodgkin's Lymphoma," Cancer, 66, 1904-1909 (1990).
Young et al., "Cancer of the Ovary," in: Cancer Principles and Practice of Oncology, DeVita et al., eds., 1162-1196 (J. B. Lippincott Co., Philadelphia
Kohn Elise
Reed Eddie
Sarosy Gisele
Criares Theodore J.
The United States of America as represented by the Department of
LandOfFree
Method for treating taxol side-effects with G-CSF does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating taxol side-effects with G-CSF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating taxol side-effects with G-CSF will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1413021